Get the Stockscreener App
2.35
7.31%
0.16
Cytomx Therapeutics Inc stock is traded at $2.35, with a volume of 1.45M.
It is up +7.31% in the last 24 hours and down -0.42% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$2.19
Open:
$2.22
24h Volume:
1.45M
Relative Volume:
0.30
Market Cap:
$189.46M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-117.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-2.08%
1M Performance:
-0.42%
6M Performance:
+176.47%
1Y Performance:
+75.37%
1-Day Range:
$2.18
$2.40
1-Week Range:
$2.18
$2.41
52-Week Range:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.35 | 345.02M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
What are the technical indicators suggesting about CytomX Therapeutics Inc.Beginner Investor Guidance For 2025 - jammulinksnews.com
Should I hold or sell CytomX Therapeutics Inc. stock in 2025Swing Trade Review With Proven Results - jammulinksnews.com
Why is CytomX Therapeutics Inc. stock attracting strong analyst attentionEntry Signal Forecasts For Consistent Profits - jammulinksnews.com
What is the risk reward ratio of investing in CytomX Therapeutics Inc. stockFinancial News Planner For Consistent Profits - jammulinksnews.com
Does CytomX Therapeutics Inc. stock perform well during market downturnsValue Investing Recommendation For Every Investor - jammulinksnews.com
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
How volatile is CytomX Therapeutics Inc. stock compared to the marketMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics: Oppenheimer initiates coverage with Outperform rating, PT $7. - AInvest
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - The Manila Times
CytomX Therapeutics Sets Q2 Earnings Date: Biotech Leader to Update on Masked Biologics Progress - Stock Titan
Oppenheimer initiates CytomX Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
How does CytomX Therapeutics Inc. compare to its industry peersEntry Signal Report For Beginners - jammulinksnews.com
What makes CytomX Therapeutics Inc. stock price move sharplyEntry Signal Report For Beginners - jammulinksnews.com
CytomX Therapeutics Inc. Reaches Critical Trendline SupportSwing Trade Entry With Volume Triggers Released - metal.it
Can CytomX Therapeutics Inc. hit a new high this monthIntraday Trend Analysis for Fast Gains Released - metal.it
CytomX Therapeutics Inc. Added to Custom Quant Screener TodayEntry and Exit Strategy Optimizer Tool Tested - metal.it
How strong is CytomX Therapeutics Inc. company’s balance sheetAI Powered Strategy For Beginners - jammulinksnews.com
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsFree Wealth Planning Blueprint - jammulinksnews.com
What institutional investors are buying CytomX Therapeutics Inc. stockGet expert analysis on top stock picks - jammulinksnews.com
What drives CytomX Therapeutics Inc. stock priceStrong return on assets - PrintWeekIndia
CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate - Yahoo Finance
What analysts say about CytomX Therapeutics Inc. stockSkyrocketing returns - PrintWeekIndia
CytomX Therapeutics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is CytomX Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - Autocar Professional
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):